CSL (CSLLY) AI Stock Analysis

• Market Cap: $56.51B
• Dividend Yield: 2.45%
• Average Volume (3M): 6.55K
• Price to Earnings (P/E): 18.8
• Beta (1Y): 0.39
• Revenue Growth: 5.08%
• EPS Growth: 13.41%
• Country: US
• Employees: 32,698
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 1.03
• Shares Outstanding: 970,302,800
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 6,551
• PEG Ratio: 1.91
• Price to Book (P/B): 3.97
• Price to Sales (P/S): 4.97
• P/FCF Ratio: 30.14
• Enterprise Value/Market Cap: 1.55
• Enterprise Value/Revenue: 5.67
• Enterprise Value/Gross Profit: 11.49
• Enterprise Value/Ebitda: 16.77
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 73 Outperform
• Price Target: $65.00 ▼(-8.26% Downside)

CSL's overall stock score is driven by strong financial performance and positive earnings call highlights, including revenue growth and strategic initiatives. However, bearish technical indicators and operational challenges in certain segments temper the score.

CSL Business Overview & Revenue Model

Company Description

CSL Limited (CSLLY) is a global biotechnology company based in Australia, specializing in the development and delivery of innovative therapies for people with serious and rare diseases. The company operates primarily in the biopharmaceutical sector, focusing on areas such as immunology, hematology, respiratory, and cardiovascular health. CSL's core products include immunoglobulin therapies, clotting factor products for hemophilia, and other specialty medicines, which are derived from human plasma and recombinant technology.

How the Company Makes Money

CSL generates revenue through the sale of its biopharmaceutical products, which are primarily derived from human plasma collected from donors. The company's key revenue streams include immunoglobulin therapies, which account for a significant portion of its sales, and recombinant therapies for hemophilia. CSL also earns revenue from its CSL Behring division, which focuses on treating bleeding disorders and immune deficiencies, and its CSL Seqirus division, which is involved in the development and distribution of vaccines. The company benefits from strategic partnerships and collaborations with healthcare providers, research institutions, and other pharmaceutical companies to enhance its product offerings and expand its market reach. Additionally, CSL's focus on research and development allows it to innovate and introduce new therapies, further driving its revenue growth.

CSL Financial Statement Overview

Summary

CSL exhibits a solid financial profile with consistent revenue growth, strong profitability, and efficient cash flow management. The company's moderate leverage and healthy return on equity further enhance its financial stability. While there are minor concerns regarding increasing debt levels and cost pressures, CSL's overall financial health remains robust, positioning it well for future growth.

Income Statement

CSL has demonstrated consistent revenue growth, with a notable increase of 5.0% in the latest year. The company maintains strong profitability, evidenced by a gross profit margin of 51.5% and a net profit margin of 19.5%. EBIT and EBITDA margins are robust at 26.7% and 33.3%, respectively, indicating efficient operations. However, the slight decline in gross profit margin over the years suggests potential cost pressures.

Balance Sheet

The balance sheet reflects a stable financial position with a debt-to-equity ratio of 0.59, indicating moderate leverage. Return on equity is healthy at 15.5%, showcasing effective use of equity capital. The equity ratio stands at 49.0%, suggesting a solid equity base. However, the gradual increase in total debt over the years warrants monitoring.

Cash Flow

CSL's cash flow performance is strong, with a free cash flow growth rate of 35.6% in the latest year, highlighting improved cash generation. The operating cash flow to net income ratio of 0.74 and free cash flow to net income ratio of 0.71 indicate efficient cash conversion. Despite fluctuations in free cash flow growth in previous years, the recent trend is positive.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	15.47B	15.43B	14.80B	13.17B	10.49B	10.27B
Gross Profit	7.64B	7.95B	7.56B	6.71B	5.66B	5.74B
EBITDA	5.23B	5.13B	4.73B	3.90B	3.46B	3.63B
Net Income	3.04B	3.00B	2.64B	2.19B	2.25B	1.78B
Balance Sheet
Total Assets	39.54B	39.40B	38.02B	36.23B	28.35B	13.63B
Cash, Cash Equivalents and Short-Term Investments	2.16B	2.16B	1.66B	1.55B	10.44B	1.36B
Total Debt	11.54B	11.50B	12.18B	12.23B	9.66B	4.36B
Total Liabilities	18.06B	18.00B	18.62B	18.41B	13.77B	7.34B
Stockholders Equity	19.40B	19.34B	17.36B	15.79B	14.58B	6.29B
Cash Flow
Free Cash Flow	3.04B	2.54B	1.51B	909.00M	1.38B	2.43B
Operating Cash Flow	3.70B	3.56B	2.76B	2.60B	2.63B	3.62B
Investing Cash Flow	-882.99M	-850.00M	-1.26B	-11.84B	-1.64B	-1.67B
Financing Cash Flow	-2.33B	-2.24B	-1.28B	456.00M	7.68B	-1.40B

CSL Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 70.85
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CSLLY, the sentiment is Negative. The current price of 70.85 is above the 20-day moving average (MA) of 64.65, above the 50-day MA of 66.18, and below the 200-day MA of 76.04, indicating a bearish trend. The MACD of -3.12 indicates Positive momentum. The RSI at 31.18 is Neutral, neither overbought nor oversold. The STOCH value of 27.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CSLLY.

CSL Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
REGN	79 Outperform	$67.70B	15.42	15.19%	0.40%	2.89%	0.50%
VRTX	78 Outperform	$105.80B	29.34	22.31%	―	10.53%	―
ARGX	76 Outperform	$51.39B	39.98	24.75%	―	89.58%	―
CSLLY	73 Outperform	$56.51B	18.76	16.36%	2.45%	5.08%	13.41%
ALNY	57 Neutral	$57.41B	1,832.32	32.73%	―	53.24%	―
BNTX	53 Neutral	$24.85B	―	-2.94%	―	7.04%	-25.24%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

CSL Corporate Events

CSL Limited’s Earnings Call: Growth Amid Challenges

CSL Limited’s recent earnings call painted a picture of robust growth tempered by operational challenges. The company reported solid revenue and profit increases, alongside strategic initiatives like a demerger and a share buyback program. However, the call also highlighted hurdles in Seqirus revenue growth, impacts from U.S. healthcare reforms, and the need for cost reductions in R&D and plasma centers, indicating some pressure points in operations.

CSL Limited Reports Strong Growth and Strategic Initiatives

CSL Limited is a global biopharmaceutical company specializing in plasma-derived therapies, vaccines, and biotechnology to address serious and complex diseases. In its latest earnings report, CSL Limited highlighted a robust financial performance with an annual revenue of $15.6 billion and a dividend of $2.92 per share. The company reported strong growth in its immunoglobulin portfolio and the successful launch of new products like Andembry, which is approved in multiple countries. CSL’s strategic initiatives include a focus on operational excellence, portfolio development, and a proposal to demerge CSL Seqirus to pursue separate growth strategies. Looking ahead, CSL remains optimistic about its ability to deliver sustainable growth and life-changing treatments, with a continued focus on innovation and strategic partnerships.